JP2020537540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537540A5 JP2020537540A5 JP2020539688A JP2020539688A JP2020537540A5 JP 2020537540 A5 JP2020537540 A5 JP 2020537540A5 JP 2020539688 A JP2020539688 A JP 2020539688A JP 2020539688 A JP2020539688 A JP 2020539688A JP 2020537540 A5 JP2020537540 A5 JP 2020537540A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- processing
- crrna
- acid according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 30
- 108020004707 nucleic acids Proteins 0.000 claims 30
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076160A JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567123P | 2017-10-02 | 2017-10-02 | |
| US62/567,123 | 2017-10-02 | ||
| US201862617138P | 2018-01-12 | 2018-01-12 | |
| US62/617,138 | 2018-01-12 | ||
| US201862697327P | 2018-07-12 | 2018-07-12 | |
| US62/697,327 | 2018-07-12 | ||
| PCT/US2018/054027 WO2019070762A1 (en) | 2017-10-02 | 2018-10-02 | RNA GUIDE CPF1 MODIFIED |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076160A Division JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537540A JP2020537540A (ja) | 2020-12-24 |
| JP2020537540A5 true JP2020537540A5 (enExample) | 2021-11-11 |
Family
ID=64184173
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539688A Pending JP2020537540A (ja) | 2017-10-02 | 2018-10-02 | 改変ｃｐｆ１ガイドｒｎａ |
| JP2024076160A Pending JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076160A Pending JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606823B2 (enExample) |
| EP (1) | EP3692154A1 (enExample) |
| JP (2) | JP2020537540A (enExample) |
| KR (2) | KR20260011199A (enExample) |
| CN (2) | CN120290559A (enExample) |
| AU (2) | AU2018345683B2 (enExample) |
| BR (1) | BR112020006601A2 (enExample) |
| CA (1) | CA3077189A1 (enExample) |
| IL (2) | IL273595B2 (enExample) |
| MX (1) | MX2020003339A (enExample) |
| SG (1) | SG11202003083PA (enExample) |
| WO (1) | WO2019070762A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201616590D0 (en) | 2016-09-29 | 2016-11-16 | Oxford Nanopore Technologies Limited | Method |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| KR20260011199A (ko) | 2017-10-02 | 2026-01-22 | 진에딧 인코포레이티드 | 변형된 cpf1 가이드 rna |
| US11268092B2 (en) | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
| KR102907245B1 (ko) * | 2018-03-14 | 2026-01-05 | 에디타스 메디신, 인코포레이티드 | 혈색소병증 치료를 위한 시스템 및 방법 |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| GB201913997D0 (en) * | 2019-09-27 | 2019-11-13 | Oxford Nanopore Tech Ltd | Method |
| WO2021127594A1 (en) * | 2019-12-18 | 2021-06-24 | Editas Medicine, Inc. | Engineered cells for therapy |
| CN113234701B (zh) * | 2020-10-20 | 2022-08-16 | 珠海舒桐医疗科技有限公司 | 一种Cpf1蛋白及基因编辑系统 |
| WO2022125329A1 (en) * | 2020-12-07 | 2022-06-16 | Inscripta, Inc. | gRNA STABILIZATION IN NUCLEIC ACID-GUIDED NICKASE EDITING |
| EP4508211A2 (en) * | 2022-04-13 | 2025-02-19 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| WO2024006672A2 (en) * | 2022-06-27 | 2024-01-04 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| IL324634A (en) | 2023-05-15 | 2026-01-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| WO2016022866A1 (en) | 2014-08-07 | 2016-02-11 | Agilent Technologies, Inc. | Cis-blocked guide rna |
| US20180320226A1 (en) | 2014-08-19 | 2018-11-08 | President And Fellows Of Harvard College | RNA-Guided Systems For Probing And Mapping Of Nucleic Acids |
| WO2016065364A1 (en) | 2014-10-24 | 2016-04-28 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
| WO2016089433A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| EP3230451B1 (en) | 2014-12-12 | 2021-04-07 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| WO2016183402A2 (en) | 2015-05-13 | 2016-11-17 | President And Fellows Of Harvard College | Methods of making and using guide rna for use with cas9 systems |
| CN107922949A (zh) | 2015-08-31 | 2018-04-17 | 安捷伦科技有限公司 | 用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法 |
| US20180237800A1 (en) | 2015-09-21 | 2018-08-23 | The Regents Of The University Of California | Compositions and methods for target nucleic acid modification |
| CA2998287A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
| EP3350327B1 (en) * | 2015-10-23 | 2018-09-26 | Caribou Biosciences, Inc. | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids |
| WO2017099494A1 (ko) * | 2015-12-08 | 2017-06-15 | 기초과학연구원 | Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도 |
| EP3443088B1 (en) | 2016-04-13 | 2024-09-18 | Editas Medicine, Inc. | Grna fusion molecules, gene editing systems, and methods of use thereof |
| EP3868880A1 (en) | 2016-04-29 | 2021-08-25 | Basf Plant Science Company GmbH | Improved methods for modification of target nucleic acids |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| EA201892810A1 (ru) | 2016-06-01 | 2019-06-28 | Квс Заат Се | Гибридные последовательности нуклеиновых кислот для геномной инженерии |
| EP3541945A4 (en) | 2016-11-18 | 2020-12-09 | Genedit Inc. | COMPOSITIONS AND METHODS OF MODIFICATION OF TARGET NUCLEIC ACIDS |
| WO2018204493A1 (en) * | 2017-05-04 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for gene editing in t cells using crispr/cpf1 |
| KR20260011199A (ko) | 2017-10-02 | 2026-01-22 | 진에딧 인코포레이티드 | 변형된 cpf1 가이드 rna |
-
2018
- 2018-10-02 KR KR1020257043505A patent/KR20260011199A/ko active Pending
- 2018-10-02 SG SG11202003083PA patent/SG11202003083PA/en unknown
- 2018-10-02 AU AU2018345683A patent/AU2018345683B2/en active Active
- 2018-10-02 KR KR1020207012638A patent/KR102907044B1/ko active Active
- 2018-10-02 EP EP18799900.8A patent/EP3692154A1/en active Pending
- 2018-10-02 IL IL273595A patent/IL273595B2/en unknown
- 2018-10-02 CN CN202510240123.0A patent/CN120290559A/zh active Pending
- 2018-10-02 WO PCT/US2018/054027 patent/WO2019070762A1/en not_active Ceased
- 2018-10-02 CN CN201880077637.7A patent/CN111770994B/zh active Active
- 2018-10-02 JP JP2020539688A patent/JP2020537540A/ja active Pending
- 2018-10-02 MX MX2020003339A patent/MX2020003339A/es unknown
- 2018-10-02 BR BR112020006601-0A patent/BR112020006601A2/pt unknown
- 2018-10-02 US US16/753,293 patent/US12606823B2/en active Active
- 2018-10-02 CA CA3077189A patent/CA3077189A1/en active Pending
-
2024
- 2024-05-08 JP JP2024076160A patent/JP2024116119A/ja active Pending
-
2025
- 2025-04-11 AU AU2025202594A patent/AU2025202594A1/en active Pending
- 2025-09-10 IL IL323269A patent/IL323269A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7672445B2 (ja) | ＣａｓＺ組成物及び使用方法 | |
| Wang et al. | Chemically modified DNA nanostructures for drug delivery | |
| Dong et al. | DNA functional materials assembled from branched DNA: design, synthesis, and applications | |
| ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
| Khisamutdinov et al. | RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape and stoichiometry | |
| Kwak et al. | Nucleic acid/organic polymer hybrid materials: synthesis, superstructures, and applications | |
| ES2743188T3 (es) | Péptidos y nanopartículas para el suministro intracelular de moléculas | |
| Lee et al. | Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing | |
| Ruff et al. | Precision templating with DNA of a virus-like particle with peptide nanostructures | |
| Lu et al. | Multifunctional DNA origami nanoplatforms for drug delivery | |
| Huang et al. | Self-assembled DNA nanostructures-based nanocarriers enabled functional nucleic acids delivery | |
| JP2018518181A5 (enExample) | ||
| JP2007504830A5 (enExample) | ||
| JP2019517268A (ja) | 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集 | |
| JP2011092201A5 (enExample) | ||
| JP2010273685A5 (enExample) | ||
| AU2002214596A1 (en) | Methods and compositions for nucleic acid delivery | |
| Kruspe et al. | Aptamers as drug delivery vehicles | |
| Finke et al. | Designer extracellular matrix based on DNA–peptide networks generated by polymerase chain reaction | |
| Bi et al. | Self-assembled multifunctional DNA nanospheres for biosensing and drug delivery into specific target cells | |
| CN110055245A (zh) | 一种dna四面体结构、制备方法及其应用 | |
| Dai et al. | Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine | |
| JP2010533735A5 (enExample) | ||
| Park et al. | Self-assembled DNA-guided RNA nanovector via step-wise dual enzyme polymerization (SDEP) for carrier-free siRNA delivery | |
| Mariconti et al. | Enzymatically active DNA-protein nanogels with tunable cross-linking density |